Investing
Should You Chase Stem Cell Stocks? (ASTM, CYTX, GERN, NBS, OSIR, STEM, KOOL)
Published:
Last Updated:
We are seeing massive gap-ups this morning in stem cell stocks. President Obama is signing an executive order which will lift the Bush ban on funding of embryonic stem cell funding. What is interesting here is that this is not really new news other than the timing and the formality. The following prices are as of 8:19 AM EST.
- Aastrom Biosciences Inc. (NASDAQ: ASTM) +87% at $0.62
- Cytori Therapeutics Inc. (NASDAQ: CYTX) +38% at $3.20
- Geron Corp. (NASDAQ: GERN) +29% at $4.99
- Neostem Inc. (AMEX: NBS) NOT TRADED
- Osiris Therapeutics Inc. (NASDAQ: OSIR) NOT TRADED…. in pact with Genzyme, but for adult stem cells.
- StemCells Inc. (NASDAQ: STEM) +55% at $2.15
- Thermogenesis Corp. (NASDAQ: KOOL) +41% at $0.57
Many of these stem cell stocks will trade more on a “vote of confidence” rather than over what this means as far as “new news” is concerned.
JON C. OGG
Find a Qualified Financial Advisor (Sponsor)
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
